About 100 reports

  • Number of Glaucoma Drugs in Early Stage Development by Molecule Type
  • PIPELINE PRODUCTS - EARLY STAGE PIPELINE

She is a co-inventor on many issued US patents and applications related to projects on cell and gene therapies.

  • Ophthalmology
  • Aerie Pharmaceuticals, Inc.
  • Alcon, Inc.
  • Allergan plc
  • Santen Pharmaceutical Co., Ltd.
  • KEY PHASE IIB/III TRIALS FOR THE PROMISING PIPELINE AGENTS THAT GLOBALDATA EXPECTS BE

Ophthalmology, ##(##), pp. ##-##. ##(##), PP. ##-##.

  • Ophthalmology
  • Forecast
  • Allergan plc
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Ophthalmology, Global, Revenue Forecast for Brolucizumab ($m), 2017-2023
  • 7.2.1 DEALS BY REGION, YEAR AND VALUE

One of the main goals of gene therapy is to overcome the effects of a disease-causing gene by delivering a functional copy of a therapeutic gene.

  • Ophthalmology
  • Adverum Biotechnologies, Inc.
  • Alcon, Inc.
  • Allergan plc
  • Astellas Pharma Inc.

Biomaterials such as liposomes, lipofectamine, and polyethyleneimine are used to overcome cellular barriers in gene therapy.

  • Ophthalmology
  • North America
  • United States
  • Market Size
  • Evonik Industries AG

The details ##.

  • Ophthalmology
  • World
  • Market Size
  • Masimo Corporation
  • Medtronic, Inc.

There are seven PGF targeting drugs, six of which are fusion proteins and one is RNAi gene therapy.

  • Ophthalmology
  • Novartis AG
  • Ophthotech Corporation
  • Regeneron Pharmaceuticals, Inc.
  • Roche Group
  • 6.1.3 BUSINESS STRATEGY

As part of the deal, Johnson & Johnson decided to provide support to the University of Pennsylvania within a new Gene Therapy Program to develop treatment for Alzheimer' s disease.

  • Ophthalmology
  • World
  • Alcon, Inc.
  • Bausch & Lomb Incorporated
  • Novartis AG

PLOS ONE; ##(##): E##.

  • Ophthalmology
  • United States
  • Allergan plc
  • Novartis AG
  • Ophthotech Corporation

Synthetic prostaglandin analogs have a large number of clinical applications; the treatment of glaucoma is one of the major ones.

  • Ophthalmology
  • Allergan plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

GENE THERAPY FOR TREATMENT OF SICKLE-CELL DISEASE Doctors should focus on wide-scale trials of gene therapy to further establish its efficacy for treatment of sickle-cell disease.

  • Ophthalmology
  • Market Size
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Others
  • Objective

You can easily book an appointment with one online.

  • Ophthalmology
  • Allergan plc
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026 ##.

  • Eye Disease
  • Ophthalmology
  • APAC
  • World
  • Market Size

Q. ##.

  • Ophthalmology
  • North America
  • United States
  • Carl Zeiss AG
  • Nidek Co., Ltd.
  • depicts the distribution of approved / clinical products targeting back of the eye
  • 3. INTRODUCTION

ONE OF THE MOST PROMINENT DRUG CLASSES IS GENE THERAPY (##%), WHICH IS FOLLOWED BY SMALL MOLECULES (##%).

  • Ophthalmology
  • United States
  • Alcon, Inc.
  • Allergan plc
  • Novartis AG
  • INDUSTRY INSIGHTS

Q. ##.

  • Ophthalmology
  • North America
  • United States
  • Market Size
  • Alcon, Inc.

Impact: ## Low; ## High F.

  • Ophthalmology
  • Bayer AG
  • Hoffmann-La Roche Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.

Therapy Area Gastrointestinal Genetic Disorders Infectious Disease Metabolic Disorders Oncology Pharmaceuticals and Healthcare Respiratory No. of Deals ## ## ## ## ## ## ## Deal Value (US$ million) NA NA NA NA NA NA NA Note: Deals include all announced pharmaceu

  • Health Services
  • Healthcare
  • Ophthalmology
  • Pharmaceutical
  • United States

You can easily book an appointment with one online.

  • Ophthalmology
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.

All therapy areas and all modalities (including small molecules, peptides, proteins, antibodies, cell and gene therapies) are in scope.

  • Ophthalmology
  • Northern Europe
  • United Kingdom
  • Abbott Medical Optics, Inc.
  • Alcon, Inc.
  • Ophthalmology Therapeutics, Global, Pipeline Programs Targeting RHO, 2017
  • Ophthalmology Therapeutics, Global, Pipeline Programs Targeting ABCA4, 2017

Human Gene Therapy Clinical Development; ##(##): ##-##.

  • Eye Disease
  • Health Services
  • Ophthalmology
  • Therapy
  • Deals & Alliance
  • PRODUCTS UNDER DEVELOPMENT BY UNIVERSITIES/INSTITUTES, H2 2018

It acts by blocking the production of the insulin receptor substrate ## (IRS-##).

  • Ophthalmology
  • United States
  • World
  • Product Initiative
  • EyeGate Pharmaceuticals, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY UNIVERSITIES/INSTITUTES, H2 2018
  • ANTISENSE OLIGONUCLEOTIDES FOR OPHTHALMOLOGY AND ONCOLOGY - DRUG PROFILE

NA : Not Available Source: Global Markets Direct Other Developmental Activities GENE THERAPY TO ACTIVATE CALRETICULIN FOR CHOROIDAL NEOVASCULARIZATION - DRUG PROFILE ICON-## - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Descri

  • Ophthalmology
  • Therapy
  • United States
  • World
  • Product Initiative
  • NT-501 - DRUG PROFILE

The therapeutic candidate acts by targeting the clarin-## (CLRN##).

  • Ophthalmology
  • Therapy
  • United States
  • World
  • Product Initiative

GENE THERAPY TO ACTIVATE MYO##A FOR USHER SYNDROME - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Gene Therapy to Activate MYO##A for Usher Syndrome Fondazione Telethon NA NA Gene therapy is under investigat

  • Ophthalmology
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • GENE THERAPY TO ACTIVATE ND4 FOR LEBER'S HEREDITARY OPTIC NEUROPATHY - DRUG PROFILE
  • Feb 02, 2018: Bascom Palmer Study Shows Gene Therapy Safe for Rare Eye Disease

The company reported that subjects were randomized ##:##:## into one of three ophthalmic solution treatment groups: SkQ## ##. ## microgram/ mL, SkQ## ##. ## microgram/ mL, or ##. ## microgram/ mL (placebo).

  • Eye Disease
  • Neurology
  • Ophthalmology
  • Therapy
  • Type 2 Diabetes
  • JUVENILE MACULAR DEGENERATION (STARGARDT DISEASE) - PIPELINE BY COPERNICUS THERAPEUTICS INC, H2 2018
  • JUVENILE MACULAR DEGENERATION (STARGARDT DISEASE) - PIPELINE BY OPHTHOTECH CORP, H2 2018

Subjects will be randomly assigned to one of three treatment arms in a ##:##:## ratio.

  • Eye Disease
  • Ophthalmology
  • Pathology
  • Pharmaceutical
  • Therapy
  • GENE THERAPY FOR GLAUCOMA AND RETINITIS PIGMENTOSA - DRUG PROFILE
  • GENE THERAPY FOR DRY MACULAR DEGENERATION AND RETINITIS PIGMENTOSA - DRUG PROFILE

" This one-time gene therapy for an inherited disease represents a first-of-its-kind breakthrough that may lay the groundwork for the development of gene therapies for other conditions that are not adequately addressed today.

  • Gene Therapy
  • Ophthalmology
  • Pharmaceutical
  • Therapy
  • Amarantus BioScience Holdings, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY UNIVERSITIES/INSTITUTES, H1 2019
  • BRIMONIDINE TARTRATE - DRUG PROFILE

NA : Not Available Source: Global Markets Direct GENE THERAPY TO TARGET MATRIX METALLOPROTEINASE ## FOR STEROID INDUCED GLAUCOMA AND OCULAR HYPERTENSION - DRUG PROFILE H-## - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Descr

  • Eye Disease
  • Health Services
  • Ophthalmology
  • United States
  • Product Initiative

Drivers and their Impact Low ## ## ## ## ## Hospitals High Impact on Key Customer Category Driver Increased Patient Population Unmet Medical Needs Improved Diagnostic Procedures Driver Increased Patient Population Unmet Medical needs Improved Diagnostic Procedures Key Low Low ## ## ## ## ##

  • Ophthalmology
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Roche Group
  • GENE THERAPY TO ACTIVATE AIPL1 FOR OPHTHALMOLOGY - DRUG PROFILE
  • Mar 21, 2018: Childrens Hospital Los Angeles Treats First Patient on the West Coast Using Gene Therapy

GENE THERAPY TO ACTIVATE AIPL## FOR LEBER' S CONGENITAL AMAUROSIS - DRUG PROFILE GENE THERAPY TO ACTIVATE AIPL## FOR OPHTHALMOLOGY - DRUG PROFILE GENE THERAPY TO ACTIVATE RETINAL GUANYLYL CYCLASE-## FOR LEBER CONGENITAL AMAUROSIS-## - DRUG PROFILE

  • Gene Therapy
  • Ophthalmology
  • Therapy
  • United States
  • Product Initiative